Experimental combo aims to help leukemia patients reach transplant
NCT ID NCT07297173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether giving chemotherapy followed by an infusion of immune cells from a partially matched donor can help patients with relapsed or refractory leukemia get to a stem cell transplant. Only 5 participants will be enrolled to check safety and side effects like graft-versus-host disease and infections. The goal is to find a better way to control the disease long enough for a transplant to work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLA-mismatched G-CSF mobilized peripheral blood mononuclear cells (donor immune cells)
- What this could lead to
- If successful, this approach could help more patients with hard-to-treat leukemia get to a stem cell transplant and possibly achieve long-term disease control.
- What could go wrong
- This is a very early Phase 1 trial with only 5 people, so safety and effectiveness are not yet known. There are serious risks like graft-versus-host disease and severe infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat leukemias
- Italian study tracks how venetoclax works for CLL patients in everyday practice
- New Triple-Drug attack on tough leukemia enters human testing
- New Three-Drug cocktail aims to outsmart tough leukemia
- New drug duo targets hard-to-treat leukemias in early trial
- Experimental drug combo takes aim at relapsed leukemia